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Abstract
Background: We previously showed that co-immunization with a protein antigen and a DNA vaccine coding for
the same antigen induces CD40
low IL-10
high tolerogenic DCs, which in turn stimulates the expansion of antigen-
specific CD4
+CD25
-Foxp3
+ regulatory T cells (CD25
- iTreg). However, it was unclear how to choose the antigen
sequence to maximize tolerogenic antigen presentation and, consequently, CD25
- iTreg induction.
Results: In the present study, we demonstrated the requirement of highly antigenic epitopes for CD25
- iTreg
induction. Firstly, we showed that the induction of CD25
- iTreg by tolerogenic DC can be blocked by anti-MHC-II
antibody. Next, both the number and the suppressive activity of CD25
- iTreg correlated positively with the overt
antigenicity of an epitope to activate T cells. Finally, in a mouse model of dermatitis, highly antigenic epitopes
derived from a flea allergen not only induced more CD25
- iTreg, but also more effectively prevented allergenic
reaction to the allergen than did weakly antigenic epitopes.
Conclusions: Our data thus indicate that efficient induction of CD25
- iTreg requires highly antigenic peptide
epitopes. This finding suggests that highly antigenic epitopes should be used for efficient induction of CD25
- iTreg
for clinical applications such as flea allergic dermatitis.
Background
The inducible regulatory T cells, or iTreg, differ from the
naturally regulatory T cells (nTreg) in that the former are
generated in the periphery through encounter with envir-
onmental antigens. It is also believed that iTreg play non-
overlapping roles, relative to nTreg, in regulating peripheral
tolerance [1-3]. Most iTreg reported to date have been
CD25
+ cells (CD4
+CD25
+Foxp3
+) ,a n di ti sw e l le s t a b l i s h e d
that their induction requires suboptimal stimulation of the
T cell receptor (TCR) and cytokines TGF-b and IL-2 [3].
The CD25
+ iTreg thus appear to derive primarily from
weakly stimulated CD4
+ T cells.
We previously identified a different subset of iTreg in
mice that is CD25
- (CD4
+CD25
-Foxp3
+ and IL-10
+TGF-
beta
+IFN-g
-). The CD25
- iTreg were induced after
co-immunization using a protein antigen and a DNA vac-
cine encoding the same antigen [4-7]. Unlike that of the
CD25
+ iTreg, the induction of the CD25- iTreg involved
the generation of CD40
low IL-10
high tolerogenic dendritic
cells (DCs), which in turn stimulated CD25
- iTreg in an
antigen-specific manner [4]. We further showed in mouse
models that this subset of iTreg was potentially useful as a
therapeutic for allergic and autoimmune diseases, such as
asthma, flea allergic dermatitis (FAD), and type 1 diabetes
(T1D) [5-7].
While the requirement for weak antigen stimulation is
well established for the induction of CD25
+ iTreg, it is
u n c l e a rw h e t h e rt h es a m ei st r u ef o rt h ei n d u c t i o no f
CD25
- iTreg. Addressing this question will allow us not
only to further differentiate the two subsets of iTreg, but
also to maximize the tolerogenicity of co-immunization
by choosing T cell epitopes of appropriate antigenicity.
In this report, we show that strong antigen stimulation is
required for efficient induction of CD25
- iTreg.
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MHC-Ag:TCR interaction is required for induction of
CD25
- iTreg
To test whether the MHC-Ag:TCR interaction is
required for the induction of CD25
- iTreg, we employed
an in vitro iTreg induction system. It involved culture of
CD4
+ T cells together with co-immunization-induced
tolerogenic DCs that presented the dominant epitope of
hen ovalbumin, OVA323-339. Using either clonotypic CD4
+ T cells from DO11.10 Balb/c mice or polyclonal CD4
+
T cells from ovalbumin-sensitized Balb/c mice, we found
that the induction of CD25
- iTreg in either case could be
blocked by anti-MHC-II antibody and, therefore, was
MHC-II-dependent. Thus, antigenic stimulation is essen-
tial for the induction of CD25
- iTreg (Figure 1).
Highly antigenic epitopes are required for efficient
induction of highly active CD25
- iTreg
To further determine how antigenicity affects CD25
-
iTreg induction, we generated a set of mutated epitopes
from OVA323-339. Using a tetramer staining-based epi-
tope competition assay, we assessed the affinity of each
of the mutated epitopes for MHC II. The result showed
the order of affinity to be OVA323-339 > MT1 > MT2 =
MT3 (Figure 2A). Consistently with this result, in vitro
T cell proliferation assays using DO11.10 CD4
+ T cells
showed a similar order in T cell stimulating activity
(Figure 2B). We therefore selected the epitopes OVA323-
339, MT1, and MT2 as probes for antigenicity studies.
To that end, Balb/c mice (I-Ad
+) were treated by co-
immunization using the DNA and protein combination
corresponding to the OVA323-339, MT1, or MT2 epitope
(designated as Co323, CoMT1, or CoMT2). Seven days
after the treatment, splenocytes were isolated and ana-
lyzed for CD25
- iTreg induction. The result showed
increased frequency of Foxp3
+ cells in the CD4
+CD25
-
(CD25
- iTreg), but not the CD4
+CD25
+ (nTreg), cell
population in the treated mice, compared to that of
untreated control mice (naïve) (Figure 3A). Importantly,
the magnitude of increase followed the order of Co323
> CoMT1 > CoMT2, suggesting that efficient induction
of CD25
- iTreg by co-immunization required highly
antigenic epitopes.
To further determine the impact of antigenicity on the
function of CD25
- iTreg, we compared the suppressive
activity of CD25
- iTreg induced by Co323, CoMT1, and
CoMT2 using an in vitro suppression assay. All CD25
-
iTreg cells suppressed the OVA323-339-specific prolifera-
tion of reporter CD4
+ T cells in co-culture as expected.
However, their relative suppressive activity followed the
s a m eo r d e ro fC o 3 2 3>C o M T 1>C o M T 2( F i g u r e3 B ) ,
suggesting that more antigenic epitopes also induce
functionally more active CD25
- iTreg cells.
To repeat this observation in vivo, we adoptively trans-
ferred CD25
- iTreg induced with the different epitopes into
Balb/c mice and then attempted to sensitize the animals
with OVA323-339 in incomplete Freund’sa d j u v a n t( I F A ) .
One week later, we isolated splenic CD4
+ T cells from the
sensitized mice and measured recall activation of CD4
+ T
effector cells by an in vitro restimulation assay. Again,
although all transferred CD25
- iTreg blocked the recall
proliferation of T cells to some degree, their relative effec-
tiveness varied with the inducing epitopes, in the order of
Co323 > CoMT1 > CoMT2 (Figure 4A). Moreover, splenic
Figure 1 MHC II blocking reduces CD25
- iTreg induction. Purified
CD4
+ T cells from Balb/c DO11.10 mice or OVA323-339-sensitized Balb/
c mice were cultured with purified tolerogenic DCs (tDC) from co-
immunized Balb/c mice or naïve DCs (nDC) from naïve Balb/c mice,
in the presence or absence of anti-MHC-II blocking mAb. CD25
- iTreg
cells (CD4
+CD25
-Foxp3
+) were counted on day 7 as percentage of
CD4
+CD25
- T cells *, p < 0.05 by the Mann-Whitney U test. Shown is
one of three independent experiments with similar results. Each dot
represents one mouse, n ≥ 5.
A
B
Figure 2 OVA323-339 mutations reduce antigenicity for T cells.
A, Summary of OVA323-339 mutations, their predicted MHC II binding
affinities, and experimental result from tetramer competition assays.
Percent of tetramer binding was calculated as: number of tetramer-
positive T cells in the presence of a competing peptide epitope /
number of tetramer-positive T cells in the absence of a competing
peptide epitope ×100%. B, Proliferation of CFSE-labeled DO11.10
CD4
+ T cells co-cultured for 4 days with tolerogenic DCs presenting
an indicated epitope. The line plots summarize the results from
three independent experiments. **, p < 0.01, n = 3.
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+ T cells isolated from the recipients showed decreased
expression of IFN-g and increased expression IL-10, the
extent of which also followed the same order (Figure 4, B-
D). Taken together, these results show that highly antigenic
epitopes are required for more efficient induction of highly
suppressive CD25
- iTreg.
Highly antigenic epitopes are also required for more
effective prevention of flea allergic dermatitis
Flea allergic dermatitis is a CD4
+ T cell-mediated allergic
reaction to flea allergen [8,9]. To extend our finding to
this disease model, we chose two antigenic epitopes from
the flea allergen FSA1, namely P66 (amino acids 66-80)
A
B
Figure 3 Induction of CD25
- iTreg cells by co-immunization depends on epitope affinity. A,C D 2 5
- iTreg (CD4
+CD25
-Foxp3
+) and nTreg
(CD4
+CD25
+Foxp3
+) induced in Balb/c mice following co-immunization were counted by flow cytometry and calculated as percentage of Foxp3
+ cells in CD4
+CD25
- and CD4
+CD25
+ T cells, respectively. Naïve, non-immunized mice. **, p < 0.01, n ≥ 5. Difference was calculated among all
groups. Each point represents one mouse. Shown is one of three independent experiments with similar results. B, Induction of highly
suppressive CD25
- iTreg cells by co-immunization depends on epitope antigenecity. CFSE labeled DO11.10 CD4
+ T cells were co-cultured with
co-immunization-induced CD25
- iTreg, in the presence of OVA323-339. Proliferation was determined by flow cytometry as divided KJ1-26
+ cells
versus total KJ1-26
+ cells. **, p < 0.01, n ≥ 5. Each point represents one mouse. Difference was calculated among all groups. Shown is one of
three independent experiments with similar results.
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have a higher affinity to MHC II (I-Ab) than P66. We
confirmed this prediction by sensitizing C57BL/6 mice
(I-Ab
+) with full-length FSA1, followed by an in vitro res-
t i m u l a t i o na s s a yu s i n go n eo ft h ee p i t o p e s .W ef o u n d
that P100 indeed induced significantly more vigorous T
cell proliferation than did P66 (Figure 5).
To see whether the difference in antigenicity influences
the induction of CD25
- iTreg cells by these two epitopes,
we prophylactically treated C57BL/6 mice with co-immu-
nization using the combination of DNA and protein
vaccines targeting each epitope (designated as Co100 or
Co66). Seven days after co-immunization, the animals
were sensitized with flea saliva extracts, followed by a
delayed-type hypersensitivity assay to determine to which
extent the prophylactic co-immunization had prevented
the development of an allergic reaction. Both the wheal
size analysis and histological examination showed a
stronger protective effect by Co100 than by Co66, as
indicated by smaller wheal diameters (Figure 6B) and
fewer mononuclear infiltrates (Figure 6C) at the reaction
site. The Co100-treated mice also had fewer mast cells
A                    B                     C  
D
Figure 4 Adoptive transfer of CD25
- iTreg cells suppresses T cell response in recipient mice.C D 4
+CD25
- T cells from OVA323-339,M T 1 ,o r
MT2 co-immunized, or from naïve Balb/c, were adoptively transferred to naïve Balb/c. The activity of the donor CD25
- iTreg was assessed by
sensitizing the recipients with OVA323-339 in IFA. A, CD4
+ T cells were isolated from the recipient after sensitization. The cells were labeled with
CFSE and restimulated with OVA323-339 in culture. Divided cells were identified by CFSE dilution and counted by flow cytometry. The result is
expressed as a percent of total CFSE
+ T cells. Shown is one of three independent experiments of similar results. B, CD4
+ T cells were isolated
from the recipients after sensitization and intracellularly immunostained for IFN-g. IFN-g
+CD4
+ T cells were counted by flow cytometry and
calculated as a percent of total CD4
+ T cells. Shown is one of three independent experiments of similar results. C &D, IFN-g and IL-10 secretion in
the supernatant of restimulated T cells. Anti-CD3 mAb (KT3) or KT3 + IL-2 + IL-4 was used in positive controls for induction of indicated
cytokines. Shown is one of three independent experiments of similar results. *, p < 0.05, **, p < 0.01, n ≥ 5. Difference was calculated among all
groups (A, B) or among Co323, CoMT1, and CoMT2 (C, D).
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Page 4 of 9and a lower level of degranulation at the reaction site
(Figure 6D). In vitro recall activation also confirmed a
weaker T cell response in the Co100 group (6A). Impor-
tantly, P100 also induced more CD25
- iTreg than P66
(Figure 6E), suggesting that P100 protected animals more
effectively by inducing more CD25
- iTreg.
To determine whether this is indeed the case, we
adoptively transferred CD25
- iTreg cells induced by
Co100 or Co66 into FSA1-sensitized mice and chal-
lenged the recipients with flea antigens. Again, recipi-
ents receiving Co100-induced CD25
- iTreg cells showed
significantly reduced DTH response than those receiving
Co66-induced counterpart (Figure 7). Collectively, these
results confirm in this disease model that highly anti-
genic epitopes are required for more efficient induction
of therapeutic CD25
- iTreg.
Discussion
We have shown for the first time that efficient induction
of highly active CD25
- iTreg cells requires highly anti-
genic epitopes for T cells. The finding is based on 1)
anti-MHC-II mAb blocked the induction CD25
- iTreg
cells in vitro (Figure 1); 2) OVA323-339 mutants with
decreased antigenicity for T cells showed decreased abil-
ity to induce active CD25
- iTreg cells (Figures 234); and
3) a similar observation was made in a mouse model of
flea allergic dermatitis, where CD25
- iTreg cells induced
b yam o r ea n t i g e n i ce p i t o p ew e r ea l s om o r ee f f e c t i v ei n
preventing the development of the disease (Figures 567).
Given that flea allergic dermatitis is a disease driven
primarily by effector CD4
+ T cells, our observation that
the CD25
- iTreg cells are effective at suppressing this dis-
ease suggests that these cells function, at least partly, by
suppressing effector CD4
+ T cells. A similar mechanism
of action has long been described for other types of Treg
cells, including both the natural (thymus-derived) and
induced CD4
+ Treg cells that display the CD25
+Foxp3
+
phenotype [10-15]. Thus, despite displaying a different
phenotype (CD25
-) and requiring strong antigenic stimu-
lation for induction, the CD25
- iTreg cells described in
the present work may exert their regulatory function
similarly to the other types of Treg cells, i.e. by inhibiting
the activity of other immune cells, particularly T cells
and antigen presenting cells, in a cell contact-dependent
and/or -independent manner. Future investigation is
needed to determine whether this is indeed the case.
iTreg cells are potentially useful as therapeutics for
allergy, autoimmune diseases, and transplant rejection
[ 7 , 1 6 - 1 8 ] .T h ep r e s e n ts t u d yt h u sh a st h et r a n s l a t i o n a l
importance by uncovering the need for choosing highly
antigenic epitopes for effective induction of CD25
- iTreg.
At present, immunosuppressant treatment is the only
means to control immune disorders and pathology,
which is unfortunately associated with many side effects,
including increased risk of infection and cancer [19,20].
In vivo induction of CD25
- iTreg cells, which are antigen-
specific, provides a novel means of controlling immune
diseases while avoiding global immunosuppression.
Despite their therapeutic potential, it remains to be
determined whether the CD25
- iTreg cells are functionally
stable for use in therapy. It is worth noting that CD25
+
iTreg, which are induced by TGF-beta [21,22]; have been
shown to lose [23] or maintain [24] the Foxp3
+ phenotype,
and suppressive activity, depending on certain conditions.
In our system, the CD25- iTreg cells appeared to remain
Foxp3
+ and function well 14 days after being induced in
vivo via co-immunization, as judged by both the in vitro
(Figure 3B and 6A) and in vivo (Figure 4 and 7) assays.
Nonetheless, these cells need to be followed for a much
longer-term in order to assess their long-term functional
stability.
It is interesting to note that strong antigenic epitopes are
a known requirement for efficient induction of effector T
cells. How does this same requirement differentiate iTreg
versus conventional T cells? Our published work suggests
that the differentiating factor is likely to be the tolerogenic
DCs generated under the condition of co-immunization,
which serve as an endogenous tolerogenic adjuvant [4-7].
It is therefore likely that either the strongly antigenic epi-
topes are involved in the generation of tolerogenic DCs or
                 
Figure 5 P100 stimulates T cells more strongly than P66. Splenic
CD4
+ T cells from flea antigen immunized C57BL/6 mice were
restimulated with P100 or P66 (5 μg/ml) in culture. T cell proliferation
was determined by an MTT assay. Concanavalin A (1 μg/ml) and BSA
(1 μg/ml) were used as positive and negative controls, respectively. *,
p < 0.05, n = 3. Shown is one of three independent experiments with
similar results.
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Figure 6 Attenuation of skin reaction by co-immunization-induced CD25
- iTreg. A, Flea antigen stimulated T cell proliferation. B, In vivo T
cell response induced by flea-specific i.d. test. C, H&E staining of skin section. The black arrows indicate infiltrating T cells. D, Mast cell number
and degranulation (black arrow) by Toluidine Blue staining. E, Seven days after co-immunizaiton, CD25
- iTreg cells were counted as a percentage
of CD4
+CD25
- T cells. Shown is one of three independent experiments with similar results. *, p < 0.05; **, p < 0.01, n ≥ 5. Difference was
calculated among all immunized groups (A, B) or all groups (E).
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tolerogenic DCs. The two possibilities are not mutually
exclusive. We are in process to investigate these
possibilities.
The complex of MHC-epitope (pMHC):TCR is pivotal
in T cell immunity, and a strong interaction between
pMHC and TCR induces stronger T cell activation
[25,26]. But controversy remains, about within this com-
plex, which affinity is effective, epitope to MHC, or pMHC
to TCR. However the issue is of theoretical importance
only in a system that employs clonotypic T cells, such as
the DO11.10 TCR-transgenic mice; in contrast, in normal
animals, the affinity of epitopes to MHC is presumably
more important because the resulting pMHC sponta-
neously selects responding T cells with the highest-affinity
TCR from a repertoire of T cells. Consistent with this
assumption, our data showed that epitopes with predicted
higher affinity to MHC also induced stronger T cell
responses in both Balb/c mice and the mouse model of
flea allergic dermatitis. Thus, in the limited wild-type ani-
mals that we have tested, it appears that strong antigeni-
city, and efficient induction of CD25
- iTreg, can be
predicted from the affinity of epitope to MHC.
Conclusions
In conclusion, we believe that highly therapeutically effec-
tive CD25
- iTreg may be induced by co-immunization
targeting one or several disease-related or specific anti-
gens, and by selecting antigenic epitopes of highest antige-
nicity for T cells as the immunogen.
Methods
Animal and reagents
Balb/c and C57/B6 mice were purchased from Beijing
Vital Laboratory Animal Technology Company, Ltd.
(Beijing, China) and Balb/c, DO11.10 were from SLAC
Laboratory Animal (Shanghai, China) and maintained
under pathogen-free conditions. All animal experiments
were approved by the Committee of Experiment Animals
of China Agricultural University. Peptides were synthe-
sized by Scipeptide Ltd. (Shanghai, China). Antibodies
for flow cytometry were purchased from BD Biosciences
(CA, USA). Flea saliva extracts were purchased from
China Medicines Corporation (Beijing, China).
Epitope design
The dominant epitope of hen ovalbumin for I-Ad
(OVA323-339: ISQAVHAAHAEINEAGR) was mutated as
reported [27] and predicted with online servers MHCPred
(http://www.ddg-pharmfac.net/mhcpred/MHCPred/) and
NetMHCII (http://www.cbs.dtu.dk/services/NetMHCII/).
Affinity scores were presented as IC50 (nM). The epitopes
of flea salivary antigen 1 (FSA1, Swiss-Prot: Q94424.3) for
I-Ab (P100: GPDWKVSKECKDPNN and P66: QEKEK
CMKFCKKVCK) were selected using MHCPred. Corre-
sponding DNA vaccines coding for OVA323-339,M T 1 ,
MT2, P100, and P66 were constructed with the pVAX1
vector, designated as pVAX1-OVA, pVAX1-MT1,
pVAX1-MT2, D100, and D66.
Antigen sensitization
Mice were immunized by subcutaneous injection (s.c.)
twice on days 0 and 7 with 100 μg peptide emulsified in
100 μl IFA (Sigma-Aldrich Inc. San Louis, USA).
Tolerogenic co-immunization
Balb/c mice were injected intramuscular (i.m.) on days 0
and 14 with 100 μge a c ho fO V A 323-339 and pVAX1-
OVA, MT1 and pVAX1-MT1, or MT2 and pVAX1-
MT2. C57BL/6 mice were similarly injected with P100
and D100, or P66 and D66.
MHC-II blocking
Purified CD4
+ T cells (5 × 10
5, R&D System, Minneapo-
l i s ,U S A ,M A G M 2 0 2 )f r o mB a l b / cD O 1 1 . 1 0m i c eo r
OVA323-339 sensitized Balb/c mice were cultured with
purified DCs (1 × 10
5, Miltenyi Biotec, Gladbach, Ger-
many, 130-052-001) from co-immunized (pVAX1-OVA
plus OVA323-339) Balb/c mice. The cells were cultured
for 7 days with or without anti-MHC II mAb (M5/
114.15.2, eBioscience, San Diego, USA).
Figure 7 Adoptive transfer of CD25
- iTreg suppresses skin
response in vivo. CD25
- iTreg from Co100 or Co66 immunized
mice were adoptively transferred into FSA1-sensitized mice. The
recipients were then challenged with flea antigens (skin test).
Histamine and PBS were used as positive and negative controls for
the skin test, respectively. *, p < 0.05, n = 3. Shown is one of three
independent experiments with similar results.
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CD4
+CD25
-Foxp3
+ iTreg were detected by immunos-
taining with anti-CD4-FITC, anti-CD25-APC, and anti-
Foxp3-PE mAbs. Intracellular IFN-g was detected in
monensin-blocked and anti-CD3 and anti-CD28 stimu-
lated T cells by intracellular staining with anti- IFN-g-
PE mAb. Data were collected with a BD FACSCalibur
and analyzed with Flowjo (Tree Star, Ashland, USA).
The supernatant of cultured T cells was also analyzed
for IFN-g and IL-10 using the FlexSet Beads Assay (BD
Biosciences).
Tetramer competition assay
PE-conjugated OVA323-339-loaded I-Ad tetramer (NIH
Tetramer Core Facility) was competed with OVA323-339
or a mutant peptide by incubation of 2 × 10
5 DO11.10
T cells, the OVA323-339 tetramer, and a competing pep-
tide together for 5 minutes. Five volumes of medium
with 10% FCS were added to stop the competition. Cells
were washed 3 times and immediately analyzed for PE-
positive T cells by flow cytometer. Data was presented
as percent of tetramer-bound T cells in total T cells.
T cell proliferation
MTT-based and CFSE-based T cell proliferation assays
were performed as described before [7,27].
In vitro suppression assay
OVA323-339-specific CD4
+ T cells from DO11.10 mice
spleen were labeled with CFSE (responder cells) and co-
cultured with co-immunization-induced CD4
+CD25
- T
cells at a 1:1 ratio (2 × 10
5 each). OVA323-339-specific
proliferation of the responder cells was analyzed by
CFSE dilution on day 4 using a FACScalibur. To block
nTreg in vivo,t w o1 0μg dose of anti-CD25 mAb (clone
3c7, eBioscience) were injected intravenously (i.v.) into
co-immunized mice at -48 h and -24 h before CD25
-
iTreg isolation.
In vivo suppression assay
Balb/c mice were injected (i.v.) with co-immunization-
induced CD25
- iTreg (2 × 10
6) on day 0. On days 1 and
8, the mice were repeatedly sensitized for the same anti-
gen. On day15, the mice were sacrificed and splenic T
cells were isolated and analyzed for recall activation by
the T cell proliferation assays.
Intradermal test (IDT) and histology
Antigen-sensitized C57BL/6 mice were challenged
intradermally (i.d.) with 10 μg of FSA (Greer Labora-
tories) on the nonlesional lateral thorax skin. PBS is
used as a sham control and histamine is used as a posi-
tive control. The diameter of the skin reaction was mea-
sured within 30 min after challenge using a calibrated
micrometer. Skin samples were collected within 30 min
of antigen challenge, fixed in 4% paraformaldehyde,
embedded in paraffin, and sectioned. Antigen retrieval
was accomplished by boiling the slides in 0.01 M citrate
buffer (pH 6.0), followed by staining with H&E for T
cells or toluidine blue for mast cells.
Statistical analysis
Pair-wise comparison was made using Student’s t test (Fig-
ures 5, 6D, 7) or the Mann-Whitney U test (Figure 1).
Comparison among three or more groups was made by
ANOVA (Figures 2B, 3, 4, 6E). Difference is considered
statistically significant if p < 0.05. * indicates p <0 . 0 5 ;
**, p < 0.01.
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